PURPOSE: Malignant pleural mesothelioma (MPM) is a highly lethal neoplasm with limited pretreatment prognostication strategies. In this report, we examine the accuracy of a previously proposed prognostic test in an independent cohort of MPM patients. This test uses simple ratios of gene expression levels to provide a novel prognostication scheme. EXPERIMENTAL DESIGN: Gene expression data using high-density oligonucleotide microarrays (approximately 22,000 genes) were obtained for a new cohort of human MPM tumors from patients undergoing similar treatments (n = 39). The relative expression levels for specific genes were also determined using real-time quantitative reverse transcription-PCR. We also used a subset of these tumors associated with widely divergent patient survival (n = 23) as a training set to identify new treatment-specific candidate prognostic molecular markers and gene ratio-based prognostic tests. The predictive nature of these newly discovered markers and gene ratio-based prognostic tests were then examined in an independent group of tumors (n = 52) using microarray data and quantitative reverse transcription-PCR. RESULTS: Previously described MPM prognostic genes and gene ratio-based prognostic tests predicted clinical outcome in 39 independent MPM tumor specimens in a statistically significant manner. Newly discovered treatment-specific prognostic genes and gene ratio-based prognostic tests were highly accurate and statistically significant when examined in an independent group of 52 tumors from patients undergoing similar treatment. CONCLUSIONS: The data support the use of gene ratios in translating gene expression data into easily reproducible, statistically validated clinical tests for the prediction of outcome in MPM.
PURPOSE:Malignant pleural mesothelioma (MPM) is a highly lethal neoplasm with limited pretreatment prognostication strategies. In this report, we examine the accuracy of a previously proposed prognostic test in an independent cohort of MPM patients. This test uses simple ratios of gene expression levels to provide a novel prognostication scheme. EXPERIMENTAL DESIGN: Gene expression data using high-density oligonucleotide microarrays (approximately 22,000 genes) were obtained for a new cohort of humanMPM tumors from patients undergoing similar treatments (n = 39). The relative expression levels for specific genes were also determined using real-time quantitative reverse transcription-PCR. We also used a subset of these tumors associated with widely divergent patient survival (n = 23) as a training set to identify new treatment-specific candidate prognostic molecular markers and gene ratio-based prognostic tests. The predictive nature of these newly discovered markers and gene ratio-based prognostic tests were then examined in an independent group of tumors (n = 52) using microarray data and quantitative reverse transcription-PCR. RESULTS: Previously described MPM prognostic genes and gene ratio-based prognostic tests predicted clinical outcome in 39 independent MPM tumor specimens in a statistically significant manner. Newly discovered treatment-specific prognostic genes and gene ratio-based prognostic tests were highly accurate and statistically significant when examined in an independent group of 52 tumors from patients undergoing similar treatment. CONCLUSIONS: The data support the use of gene ratios in translating gene expression data into easily reproducible, statistically validated clinical tests for the prediction of outcome in MPM.
Authors: D J Sugarbaker; R M Flores; M T Jaklitsch; W G Richards; G M Strauss; J M Corson; M M DeCamp; S J Swanson; R Bueno; J M Lukanich; E H Baldini; S J Mentzer Journal: J Thorac Cardiovasc Surg Date: 1999-01 Impact factor: 5.209
Authors: Gavin J Gordon; Levi A Deters; Matthew D Nitz; Barry C Lieberman; Beow Y Yeap; Raphael Bueno Journal: J Thorac Cardiovasc Surg Date: 2006-09 Impact factor: 5.209
Authors: Assunta De Rienzo; Beow Y Yeap; Edmund S Cibas; William G Richards; Lingsheng Dong; Ritu R Gill; David J Sugarbaker; Raphael Bueno Journal: J Mol Diagn Date: 2014-01-09 Impact factor: 5.568
Authors: Sheelu Varghese; Zhaorong Chen; David L Bartlett; James F Pingpank; Steven K Libutti; Seth M Steinberg; John Wunderlich; H Richard Alexander Journal: Cancer Date: 2010-09-13 Impact factor: 6.860
Authors: Assunta De Rienzo; Lingsheng Dong; Beow Y Yeap; Roderick V Jensen; William G Richards; Gavin J Gordon; David J Sugarbaker; Raphael Bueno Journal: Clin Cancer Res Date: 2010-11-18 Impact factor: 12.531
Authors: Assunta De Rienzo; Robert W Cook; Jeff Wilkinson; Corinne E Gustafson; Waqas Amin; Clare E Johnson; Kristen M Oelschlager; Derek J Maetzold; John F Stone; Michael D Feldman; Michael J Becich; Beow Y Yeap; William G Richards; Raphael Bueno Journal: J Mol Diagn Date: 2016-11-15 Impact factor: 5.568
Authors: Assunta De Rienzo; William G Richards; Beow Y Yeap; Melissa H Coleman; Peter E Sugarbaker; Lucian R Chirieac; Yaoyu E Wang; John Quackenbush; Roderick V Jensen; Raphael Bueno Journal: Clin Cancer Res Date: 2013-03-14 Impact factor: 12.531
Authors: Gavin J Gordon; Lingsheng Dong; Beow Y Yeap; William G Richards; Jonathan N Glickman; Heather Edenfield; Madhubalan Mani; Richard Colquitt; Gautam Maulik; Branden Van Oss; David J Sugarbaker; Raphael Bueno Journal: J Natl Cancer Inst Date: 2009-04-28 Impact factor: 13.506